Violet Defense Offers Affordable Disinfection as a Service to Respond to COVID-19 Surges

UV disinfection products safely kill COVID-19, flu, and Norovirus to protect people, industries, and the environment

Violet Defense notes as the Omicron coronavirus variant sweeps the country and COVID-19 cases surge, many businesses are trying to ride it out with standard or even diminished precautions.

Violet Defense, a UV disinfection technology company, provides a better, sustainable, and long-term solution that is now available as a service.

Violet Defense is the developer of patented ultraviolet (UV) light technology proven in laboratory tests to kill bacteria and viruses, including coronavirus, norovirus, E. coli, C. diff, C. auris, Salmonella and MRSA. Its pulsed Xenon solution can be permanently installed or used in portable units.

Public-serving organizations are trying to remain open during the latest coronavirus resurgence, using standard chemical disinfection methods that have been insufficient and put workers at risk. Meanwhile, employees and customers are less often using precautions like social distancing and masks. That translates to increased risk of infection.

“The rapid spread of the latest COVID-19 variant has shown clearly that we don’t have the proper protections in place,” said Violet Defense CEO Terrance Berland. “Superior disinfection practices are not a luxury to aspire to anymore, they are a necessity, and UV disinfection is a proven way to keep people safe.”

Schools, hospitals, and all types of businesses are struggling to stay open as large numbers of employees become ill and quarantine. Even after the coronavirus pandemic subsides, illnesses like influenza will pose the same problem. That reminds us that vaccination, rapid testing and contact tracing alone cannot keep the public safe – frequent, thorough and effective disinfection is also vital.

With that in mind, Violet Defense is developing a new business model, Disinfection as a Service, where businesses can install its UV disinfection products via a lease-style arrangement, making it an operating expense instead of a capital purchase. The small Violet Defense unit would cost little more than $1 per disinfection cycle.

“We have a responsibility to protect our children, first responders, teachers, business owners – everyone. In that sense, disinfection is essentially a public service,” Berland said. “With Violet Defense’s new program, it’s an easy choice to get the best disinfection possible – at little more than $1 per disinfection cycle, how can you afford not to?”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version